Conmed CORP (CNMD) — SEC Filings

Overview

Conmed CORP (CNMD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 7, 2026: CONMED Corp filed an Annual Report to Security Holders (ARS) on April 7, 2026, for the period ending December 31, 2025. The filing, with accession number 0001140361-26-013600, provides details on the company's performance and operations for the fiscal year. CONMED Corp is headquartered at 11311 Conc

Sentiment Summary

Across 46 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 41 neutral, 1 mixed. The dominant filing sentiment for Conmed CORP is neutral.

Filing Type Overview

Conmed CORP (CNMD) has filed 1 ARS, 2 DEFA14A, 27 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 6 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (46)

• CONMED Corp Files Annual Report for FY 2025 — ARS · Apr 7, 2026 Risk: low
  CONMED Corp filed an Annual Report to Security Holders (ARS) on April 7, 2026, for the period ending December 31, 2025. The filing, with accession number 000114
• DEFA14A Filing — DEFA14A · Apr 7, 2026
• 8-K Filing — 8-K · Dec 5, 2025
• CONMED's Q3 Net Income Plunges 94% Despite Sales Growth — 10-Q · Nov 6, 2025 Risk: high
  CONMED Corp reported a significant decline in net income for the three and nine months ended September 30, 2025, despite an increase in net sales. For the three
• CONMED Corp Files 8-K on Financials — 8-K · Nov 5, 2025 Risk: low
  CONMED Corporation filed an 8-K on November 5, 2025, reporting on its Results of Operations and Financial Condition, and filing Financial Statements and Exhibit
• CONMED Corp Files 8-K on Officer/Director Changes — 8-K · Sep 9, 2025 Risk: medium
  CONMED Corporation filed an 8-K on September 9, 2025, reporting events as of September 8, 2025. The filing primarily concerns the departure of directors or cert
• CONMED Corp Files 8-K for Other Event — 8-K · Aug 8, 2025 Risk: low
  CONMED Corporation filed an 8-K on August 8, 2025, reporting an "Other Event" that occurred on August 7, 2025. The filing does not provide specific details abou
• CONMED Swings to Q2 Loss Amidst Declining Profitability — 10-Q · Jul 31, 2025 Risk: high
  CONMED Corp reported a net loss of $1.5 million for the second quarter ended June 30, 2025, a significant decline from a net income of $10.2 million in the prio
• CONMED Corp Files 8-K on Financials — 8-K · Jul 30, 2025 Risk: low
  CONMED Corporation filed an 8-K on July 30, 2025, reporting on its results of operations and financial condition, as well as filing financial statements and exh
• CONMED Corp Files 8-K: Director Changes & Compensation Updates — 8-K · Jul 7, 2025 Risk: low
  On July 7, 2025, CONMED Corporation filed an 8-K report detailing the departure of a director, the election of new directors, and updates to executive compensat
• CONMED Corp Files 8-K for Material Definitive Agreement — 8-K · Jun 16, 2025 Risk: medium
  On June 10, 2025, CONMED Corporation entered into a material definitive agreement related to a direct financial obligation. The company, incorporated in Delawar
• CONMED Corp Announces Executive, Board Changes and Shareholder Votes — 8-K · May 21, 2025 Risk: medium
  CONMED Corporation announced on May 19, 2025, several key executive and board changes. The company elected new directors, appointed new officers, and adjusted c
• CONMED Corp Files Additional Proxy Materials — DEFA14A · May 6, 2025 Risk: low
  CONMED Corporation filed a Definitive Additional Materials proxy statement on May 6, 2025. This filing relates to materials previously submitted to the SEC. The
• CONMED Corp Files Q1 2025 10-Q — 10-Q · May 1, 2025 Risk: low
  CONMED Corporation filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter o
• CONMED Corp Files 8-K on Financials — 8-K · Apr 30, 2025 Risk: low
  CONMED Corporation filed an 8-K on April 30, 2025, reporting on its Results of Operations and Financial Condition. The filing includes financial statements and
• CONMED Corp DEF 14A: Executive Compensation Details — DEF 14A · Apr 8, 2025 Risk: low
  CONMED Corp filed a DEF 14A on April 8, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on
• CONMED Corp Files 8-K on Director and Officer Changes — 8-K · Apr 1, 2025 Risk: medium
  On April 1, 2025, CONMED Corporation filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indicat
• CONMED Corp Files 8-K: Board & Executive Changes — 8-K · Feb 25, 2025 Risk: medium
  On February 24, 2025, CONMED Corporation filed an 8-K report detailing changes in its board of directors and executive officers. The filing includes information
• CONMED Corp Files 2024 10-K — 10-K · Feb 18, 2025 Risk: medium
  CONMED Corp filed its 10-K for the fiscal year ending December 31, 2024, on February 18, 2025. The company, based in Largo, Florida, operates in the electromedi
• CONMED Corp Files 8-K on Financials — 8-K · Feb 5, 2025 Risk: low
  CONMED Corporation filed an 8-K on February 5, 2025, reporting on its results of operations and financial condition, and including financial statements and exhi
• CONMED Corp Files 8-K — 8-K · Jan 13, 2025 Risk: low
  CONMED Corporation filed an 8-K on January 13, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain spe
• CONMED Corp Files 8-K for Other Event — 8-K · Dec 10, 2024 Risk: medium
  CONMED Corporation filed an 8-K on December 10, 2024, reporting an "Other Event" that occurred on December 9, 2024. The filing does not contain specific details
• SC 13G/A Filing — SC 13G/A · Nov 13, 2024
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• CONMED Corp Files Q3 2024 10-Q — 10-Q · Oct 31, 2024 Risk: low
  CONMED Corp filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third quarter and
• CONMED Corp Files 8-K on Operations, Personnel Changes — 8-K · Oct 30, 2024 Risk: medium
  CONMED Corporation filed an 8-K on October 30, 2024, reporting on its results of operations and financial condition. The filing also disclosed the departure of
• CONMED Corp Files 8-K on Operations and Financials — 8-K · Oct 4, 2024 Risk: low
  CONMED Corporation filed an 8-K on October 4, 2024, to report on its results of operations and financial condition, as well as to file financial statements and
• CONMED Corp Files Routine 8-K Report — 8-K · Sep 30, 2024 Risk: low
  On September 30, 2024, CONMED Corporation filed an 8-K report. The filing primarily serves as a current report and does not disclose specific material events or
• CONMED Corp Announces Executive and Director Changes — 8-K · Sep 20, 2024 Risk: medium
  CONMED Corporation announced on September 16, 2024, changes in its executive team and board of directors. Specifically, the company reported the departure of Di
• CONMED Corp Files 8-K: Director & Officer Changes — 8-K · Aug 14, 2024 Risk: low
  CONMED Corporation filed an 8-K on August 14, 2024, reporting changes in its board of directors and executive officers, as well as updates to compensatory arran
• CONMED Corp Files 8-K Report — 8-K · Aug 9, 2024 Risk: low
  On August 9, 2024, CONMED Corporation filed an 8-K report. The filing indicates that the company is providing information under "Other Events" and is not report
• CONMED Corp Files Q2 2024 10-Q — 10-Q · Aug 1, 2024 Risk: low
  CONMED Corporation filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second quarter o
• CONMED Corp Files 8-K on Financials — 8-K · Jul 31, 2024 Risk: low
  CONMED Corporation filed an 8-K on July 31, 2024, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits.
• CONMED Appoints Todd W. Simmons as CFO — 8-K · May 28, 2024 Risk: low
  CONMED Corporation announced on May 22, 2024, the appointment of Todd W. Simmons as Chief Financial Officer, effective immediately. Simmons previously served as
• CONMED Corp Files 8-K for Shareholder Votes & Other Events — 8-K · May 22, 2024 Risk: low
  CONMED Corporation filed an 8-K on May 22, 2024, to report on matters submitted to a vote of security holders and other events. The filing does not contain spec
• CONMED Corp Files 10-Q for Period Ending March 31, 2024 — 10-Q · Apr 25, 2024 Risk: low
  CONMED Corp (CNMD) filed a Quarterly Report (10-Q) with the SEC on April 25, 2024. CONMED Corp filed a 10-Q report for the period ending March 31, 2024. The fil
• CONMED CFO Departs, Interim Appointed — 8-K · Apr 24, 2024 Risk: medium
  CONMED Corporation announced on April 19, 2024, the departure of its Chief Financial Officer, Todd W. Garner. The company has appointed Robert D. Small as the i
• CONMED Corp Files 8-K on Financials — 8-K · Apr 24, 2024 Risk: low
  CONMED Corporation filed an 8-K on April 24, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and
• CONMED Corp Files Definitive Proxy Statement (DEF 14A) — DEF 14A · Apr 8, 2024 Risk: low
  CONMED Corp (CNMD) filed a Proxy Statement (DEF 14A) with the SEC on April 8, 2024. CONMED Corp filed a Definitive Proxy Statement (DEF 14A) on April 8, 2024. T
• CONMED Corp Files 2023 Annual Report on Form 10-K — 10-K · Feb 28, 2024 Risk: medium
  CONMED Corp (CNMD) filed a Annual Report (10-K) with the SEC on February 28, 2024. CONMED Corp filed its 10-K report for the fiscal year ending December 31, 202
• CONMED Files 8-K Current Report on Feb 26 Event — 8-K · Feb 27, 2024 Risk: low
  CONMED Corporation filed an 8-K on February 27, 2024, reporting an event that occurred on February 26, 2024. This filing is a Current Report under Section 13 or
• Vanguard Trims CONMED Stake to 11.7% as of Dec 29, 2023 — SC 13G/A · Feb 13, 2024 Risk: low
  The Vanguard Group, a major investment firm, filed an amendment to its Schedule 13G on February 13, 2024, indicating its ownership of 3,745,437 shares of CONMED
• EARNEST Partners Cuts CONMED Stake to 6.1% — SC 13G/A · Feb 12, 2024 Risk: medium
  EARNEST Partners, LLC, an investment advisor based in Atlanta, GA, filed an amended Schedule 13G/A on February 12, 2024, indicating its ownership of 1,891,550 s
• Capital Research Global Investors Trims CONMED Stake to 8.7% — SC 13G/A · Feb 9, 2024 Risk: medium
  Capital Research Global Investors, a major institutional investor, filed an amended SC 13G/A on February 9, 2024, disclosing its ownership in CONMED Corp. As of
• CONMED Q4 Net Sales Up 10.1% to $340.4M; FY Sales $1.24B — 8-K · Jan 31, 2024
  CONMED Corporation filed an 8-K on January 31, 2024, to announce its financial results for the fourth quarter and full year ended December 31, 2023. The company
• BlackRock Amends CONMED Stake, Files 19th SC 13G/A — SC 13G/A · Jan 22, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 22, 2024, indicating a change in their ownership of CONMED Corp. common stock as of December 31, 2023. This

Risk Profile

Risk Assessment: Of CNMD's 40 recent filings, 2 were flagged as high-risk, 13 as medium-risk, and 25 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Conmed CORP's most recent 10-Q filing (Nov 6, 2025):

• Revenue: $337.9M
• Net Income: $2.86M
• EPS: $0.09
• Debt-to-Equity: 1.30
• Cash Position: $38.9M
• Operating Margin: 3.5%
• Total Assets: $2.322B
• Total Debt: $853.753M

Key Executives

• Hollie Foust
• Robert J. Conway, Jr.
• Todd W. Simmons
• Todd W. Garner
• Robert D. Small

Industry Context

CONMED operates in the medical device industry, a sector characterized by innovation, regulatory scrutiny, and intense competition. Companies in this space often face pressures from healthcare providers to manage costs while delivering advanced solutions. Trends include a focus on minimally invasive procedures, digital health integration, and supply chain resilience.

Top Tags

financial-reporting (8) · sec-filing (6) · 8-K (6) · corporate-governance (6) · financials (5) · executive-compensation (5) · 10-Q (4) · operations (4) · 8-k (4) · institutional-ownership (4)

Key Numbers

• ARS Document Size: 12582912 — Size of the primary ARS PDF document.
• Submission Text File Size: 17143090 — Size of the complete submission text file.
• Net Sales (Q3 2025): $337.9M — Increased by 6.7% from $316.7M in Q3 2024
• Net Income (Q3 2025): $2.86M — Decreased by 94.2% from $48.98M in Q3 2024
• Diluted EPS (Q3 2025): $0.09 — Fell from $1.57 in Q3 2024
• Cost of Sales (Q3 2025): $171.8M — Increased by 24.8% from $137.7M in Q3 2024
• Selling & Admin Expense (Q3 2025): $140.3M — Increased by 40.7% from $99.7M in Q3 2024
• Net Sales (YTD Sept 2025): $1.001B — Increased by 4.2% from $961.07M in YTD Sept 2024
• Net Income (YTD Sept 2025): $30.3M — Decreased by 69.3% from $98.67M in YTD Sept 2024
• Long-term Debt (Sept 30, 2025): $853.0M — Decreased from $905.07M at Dec 31, 2024
• Cash & Cash Equivalents (Sept 30, 2025): $38.9M — Increased from $24.46M at Dec 31, 2024
• Shares Outstanding (Nov 3, 2025): 30,967,954 — Current common stock shares outstanding
• SEC File Number: 001-39218 — Identifies the company's filing with the SEC.
• EIN: 16-0977505 — Employer Identification Number for tax purposes.
• IRS Employer Identification No.: 16-0977505 — Tax identification number for CONMED Corporation.

Forward-Looking Statements

• {"claim":"Vanguard will maintain a significant, but potentially slightly reduced, stake in CONMED Corp over the next year.","entity":"The Vanguard Group","targetDate":"December 29, 2024","confidence":"medium"}
• {"claim":"CONMED Corporation's stock price may experience downward pressure due to the reduced institutional ownership.","entity":"CONMED Corporation","targetDate":"Q1 2024","confidence":"medium"}
• {"claim":"CONMED's stock price may experience short-term volatility as investors react to the news of Capital Research Global Investors reducing its stake.","entity":"CONMED Corp.","targetDate":"1 week","confidence":"medium"}

Related Companies

SYK · ZBH

Frequently Asked Questions